Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kinect 4: Valbenazine Safety in Tardive Dyskinesia
NCT02405091Phase 3Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Mar 2015
- Primary completion
- Mar 2017
- Modality
- Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of valbenazine in tardive dyskinesia (TD), sponsored by Neurocrine Biosciences. Started Mar 2015; status: completed.
02
Drugs
valbenazine
03
Conditions
tardive dyskinesia (TD)
Beyond the preview
Go deeper on NCT02405091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02405091.